1 results match your criteria: "and Dermatologic Surgicenter in Philadelphia[Affiliation]"
Talimogene Laherparepvec in Non-Melanoma Cancers.
J Clin Aesthet Dermatol
November 2021
Dr. Salloum is with the Department of Dermatology at Saint George Hospital University Medical Center in Beirut, Lebanon, and Dermatologic Surgicenter in Philadelphia, Pennsylvania.
Background: Talimogene laherparepvec (T-VEC) is the first oncolytic virus therapy approved by the United States Food and Drug Administration (in 2015) for the treatment of advanced-stage melanoma. Despite a paucity of Phase III trials for T-VEC as a therapy for non-melanoma cancers, successful off-label use of T-VEC for this purpose has been reported in the literature.
Objective: We sought to review the literature describing T-VEC as a treatment for non-melanoma cancer.